IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: University of Zürich
Serial No.: 18/012,122
Filing or 371(c) Date: December 21, 2022
Entitled: Compositions and Kits of Parts Comprising N,N-Dimethyltryptamine and Harmine and Their Use in Therapy

Confirmation No.: 5956
Group No.:
Examiner:

THIRD-PARTY PRE-ISSUANCE SUBMISSION

Examiner:

The following documents, which are also identified in the Form PTO/SB/429 filed herewith, are submitted for your consideration as being of potential relevance to the examination of the present application

1. Intl. Pat. Doc. No. WO2019081764A1 "Combination product for the treatment of neurological and/or psychiatric disorders" (Published May 2, 2019)
2. SOUZA (2019) "Validation of an analytical method for the determination of the main ayahuasca active compounds and application to real ayahuasca samples from Brazil" Journal of Chromatography. 1124: 197-203
3. INNEREXPLORER, "There Is Nothing To Be Afraid Of. Huasca Combo (B. caapi Extract & DMT Fumarate)" October 15, 2017; retrieved from Erowid Experience Vaults. https://erowid.org/experiences/exp.php?ID=108203, retrieved October 15, 2017
4. 1108, "Threshold Oral Experience Huasca Combo (Syrian Rue & M. tenuiflora)" December 31, 2009; retrieved from Erowid Experience Vaults. https://erowid.org/experiences/exp.php?ID=76862, retrieved December 31, 2009
5. OSORIO (2015) "Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report" Revista Brasileira de Psiquiatria. 37 (1): 13-20
6. NUNES (2016) "Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans" Journal of Psychoactive Drugs. 48(3): 195-205
7. INSERRA (2018) "Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process" Frontier in Pharmacology. 9: 330
8. RENELLI (2020) "An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders" Eating and Weight Disorders. 25(2): 437-444
9. CAMERON (2018) "Dark Classics in Chemical Neuroscience: N,N-Dimethyltryptamine (DMT)" ACS chemical neuroscience. 9(10): 2344-2357
10. DMTNEXUS, "DMT Fumarate" February 22, 2013; retrieved from DMT-Nexus. https://wiki.dmt-nexus.me/DMT_Fumarate, retrieved February 22, 2013
11. STRASSMAN (1994) "Dose-Response Study of N,N-Dimethyltryptamine in Humans" Archives of General Psychiatry. 51(2): 85-97
12. EROWID, "DMT Dosage" February 21, 2015; retrieved from Erowid. https://erowid.org/chemicals/dmt/dmt_dose.shtml, retrieved February 21, 2015

13. U.S. Pat. App. Doc. No. US2020/0179349A1 “Methods Of Treating Food Allergy Conditions” (Published June 11, 2020)
14. GALLIMORE (2016) “A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience” Frontiers in Pharmacology. 7:1-11
15. EROWID, “Tihkal The Continuation Alexander & Ann Shulgin #14. HARMINE b-CARBOLINE, 7-METHOXY; 7-METHOXY-b-CARBOLINE; BANISTERINE; YAGEINE; TELEPATHINE; LEUCOHARMINE” February 21, 2015; retrieved from Erowid. https://erowid.org/library/books_online/tihkal/tihkal14.shtml, retrieved February 21, 2015
16. SHROOMERY, “Re: Ayahuasca failure (Syrian Rue and MImosa) [Re: thoraxx]” March 19, 2016; retrieved from Shroomery. https://www.shroomery.org/forums/showflat.php/Number/23022449; retrieved March 19, 2016

Attached hereto is a claim chart providing a concise description of the relevance of each reference in the document list of the elements of the presently pending claims.

U.S.S.N. 18/012,122 Pending Claims	References
1. A kit of parts comprising: (a) N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and (b) harmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.	1. Intl. Pat. Doc. No. WO2019081764A1 "Combination product for the treatment of neurological and/or psychiatric disorders" (Published May 2, 2019) From **Page 18 lines 21-29** "Preferably, the compound described by **formula (I) is N,N-dimethyltryptamine**, N,N- diethyltryptamine, N,N-dipropyltryptamine, N,N-diisopropyltryptamine, 5-methoxy-N,N-dimethyltryptamine…" From **page 27 lines 22-33** "In a preferred embodiment, any of the aforementioned combination products may **further comprise a monoamine oxidase inhibitor which can boost the effectiveness of the compound** described by formula (I). **Preferably, the monoamine oxidase inhibitor is: a) a β-carboline such as harmine (CAS No. 442-51 -3)**, harmaline (CAS No. 304-21 -2), tetrahydroharmine (CAS No. 17019-01 -1), harmol (CAS No. 487-03-6), and/or harmalol (CAS No. 525-57-5), their salts and/or esters;…" From **page 27 lines 35-37 to page 28 lines 1-5** "**In a preferred embodiment, the combination product is a mixture of the compound described by formula (I) and the 5-HT2A receptor antagonist, i.e. the combination product is a composition**. In an alternative embodiment, the compound described by formula (I) and the 5-HT2A receptor antagonist are **physically separated**. For example, **the compound described by formula (I) could be contained in one blister pack while the 5-HT2A receptor antagonist is contained within a separate blister pack or the compound described by formula (I) and the 5- HT2A receptor antagonist could be contained in the same pill but be physically separated by a barrier, such as a gelatin barrier.**" From **page 18 lines 10-14** "Rather than a complex mixture of natural compounds derived from vegetation, **the two active ingredients of the present invention may be substantially pure and may or may not be combined with pharmaceutically acceptable carrier and/or diluent** as well as other controlled substances. In a preferred embodiment, the compound described by formula (I) is substantially pure." 2. SOUZA (2019) "Validation of an analytical method for the determination of the main ayahuasca active compounds and application to real ayahuasca samples from Brazil" Journal of Chromatography. 1124: 197-203 From abstract "**Ayahuasca is a brew prepared from the water decoction of two Amazonian plants**, which is legally used for religious, cultural or therapeutic activities. The potential use of ayahuasca as a natural or phytotherapeutic drug is directly linked to

	the action of its active compounds and their connection with the **therapeutic efficacy** of the beverage. In this context, the aim of the present study was to establish a selective, sensitive and reproducible analytical method for the **quantification of the main active ayahuasca compounds**. **Thirty-eight** samples from the state of São Paulo, Brazil, **were analyzed and the simultaneous quantifications of N,N-dimethyltryptamine (DMT)**, tetrahydroharmine (THH), **harmine (HME)** and harmaline (HML) were performed. This study enabled the development of a fast validated analytical method with minimal matrix interference and high reproducibility for the tracing of active ayahuasca compound concentrations for the first time. This method is important as an auxiliary tool for the study of active compound effects in biological responses using different multi-omic platforms." From **page 199** "In order to calculate linearity, three analytical curves with seven points each were prepared, varying analyte concentrations according to the intervals described in the Suppl. Table 2. The equations of the lines, the correlation (r) and determination coefficients (R2) and the range of the values obtained for the statistical residuals were then determined from the analytical curves constructed for the four analytes **(Table 2). Based on the variance and linear regression, the linearity results were able to provide the concentration ranges for the determination of target analyte concentrations** [26,27]." From **page 200** **Table 2** Regression data for each ayahuasca analyte. Linearity (n = 21) / Concentration range DMT (1.5–15.0 mg/L) / THH (3.5–35.0 mg/L) / HME (6.0–60.0 mg/L) / HML (1.0–5.5 mg/L) r: 0.9956 / 0.9982 / 0.9966 / 0.9969 R^2: 0.9912 / 0.9963 / 0.9933 / 0.9939 Linear equation: y = 0.2644× + 0.4749 / y = 0.0925× + 0.1756 / y = 0.1798× + 1.282 / y = 0.1608× + 0.0766 Residual range: −0.16 to 0.23 / −0.07 to 0.18 / −0.33 to 0.50 / −0.029 to 0.032
2. A composition comprising N,N-dimethyltryptamine fumarate and harmine hydrochloride.	16. SHROOMERY, "Re: Ayahuasca failure (Syrian Rue and MImosa) [Re: thoraxx]" March 19, 2016; retrieved from Shroomery. https://www.shroomery.org/forums/showflat.php/Number/23022449; retrieved March 19, 2016 From **webpage** "When using plain rue and root bark, you're throwing darts. If you wanna get serious, **order a gram of Harmine hcl** + Harmaline hcl, **and mix that with some DMT fumarate**. You can dial in your dose more easily and it has always been effective that way for me and others. **I use about 200mg harmalas + 150mg dmt**." From **webpage** "Aya is elusive. I struggled a lot to get a successful experience. **It came down to extracting the MAOI from caapi, and converting some DMT to the salt form, mixed together in 1 capsule down the hatch.**"

	9. CAMERON (2018) "Dark Classics in Chemical Neuroscience: N,N-Dimethyltryptamine (DMT)" ACS chemical neuroscience. 9(10): 2344-2357 From **page 2346** "Typically, DMT is purified via sublimation of the free base under reduced pressure, crystallization/recrystallization of a DMT salt form, or a combination of the two. **The fumarate salt of DMT is perhaps one of the easiest forms to work with and store as other salts** (e.g., acetate, citrate, hydrochloride, etc.) tend to be hygroscopic. As with most indole-containing compounds, DMT should be stored in a dark freezer to avoid decomposition." 11. STRASSMAN (1994) "Dose-Response Study of N,N-Dimethyltryptamine in Humans" Archives of General Psychiatry. 51(2): 85-97 From **page 86** "**Dimethyltryptamine fumarate** was prepared by David E. Nichols, PhD, Purdue University, West Lafayette, Ind. Purity, determined by gas chromatography-mass spectrometry and high-performance liquid chromatography, was greater than 99.9%. It was prepared for **clinical administration** by the Inpatient Pharmacy of the University of New Mexico Hospital in vials containing 40 mg/mL." 10. DMTNEXUS, "DMT Fumarate" February 22, 2013; retrieved from DMT-Nexus. https://wiki.dmt-nexus.me/DMT_Fumarate, retrieved February 22, 2013 From **webpage** " **Advantages** **DMT fumarate is more water soluble, more stable, has a longer shelf life, is much easier to crystallize, has a higher melting point, is less waxy, and easier to form into a powder than freebase DMT. Because of these characteristics DMT fumarate is much preferred over freebase DMT.** Freebase DMT has no benefits other than the fact that it is easily vaporized." 3. INNEREXPLORER, "There Is Nothing To Be Afraid Of. Huasca Combo (B. caapi Extract & DMT Fumarate)" October 15, 2017;

retrieved from Erowid Experience Vaults. https://erowid.org/experiences/exp.php?ID=108203, retrieved October 15, 2017

From **webpage**

DOSE: T+ 0:00		oral	Banisteriopsis caapi	(extract)
T+ 0:20	50 mg	oral	DMT	

From **webpage** "I have had several experiences with **Caapi extract (180 mg harmine** and 180 mg tetrahydroharmine) as well as with vine-only brews, but I have taken a pretty long break from both and have lately felt that this is **the best medicine for me** to work with."

From **webpage** "**After a few successful and very rewarding sessions with the Caapi extract**, **I thought it would be good to add in some DMT.** It just so happens that I had been planning on converting a gram of DMT freebase to **DMT Fumarate, which is the ideal form of DMT for oral** as well as IV/IM administration. At first, I was drawn to the idea of IM administration but I realized that I would need to spend a good deal of time preparing the proper safety precautions in order to minimize error or accidental injury. **As such, the best route seemed to be oral in combination with the Caapi extract**.

Experiment #1:

I recently experienced Caapi extract with 21mg DMT Fumarate (.32mg/kg) which is a very very small dose, barely threshold. I did this purposely in order to ease my way into working with this powerful combination again. **The comeup on the Caapi extract was powerful as usual and I delayed taking the DMT an extra 20 minutes, taking it at t+0:40 instead of t+0:20.** I don't think that would have reduced the efficacy of the DMT at all, but rather it was the very low dose of DMT that led to very little effects. It was interesting that once I felt the DMT come on I felt very very tired and almost felt like I slept through the whole experience, though the two purges that I had were very emotionally based and were centered around purging negative thought patterns I have kept inside.

In my next experiment, **I plan on increasing the dose to 35mg DMT (.54mg/kg) in combination with the Caapi extract**. I think this will be a bit more of a trip and will give me a better sense of my flight navigation skills. I am deliberately taking my time with this to get to know these medicines I am deliberately taking my time with this to get

to know **these medicines as they work together** and how best to navigate the spaces they open up. This is how the shamans came to understand their work with the plants. Gradual increases in doses and getting to know the spirits of these medicines.

Experiment #2:

After careful research and reflection, I prepared to take my next journey with the **Caapi extract (which contains 180mg tetrahydroharmine and 180mg harmine) in combination with 50mg DMT Fumarate (.781mg/kg**…

… **I poured the Caapi extract into a glass of grapefruit juice** and allowed it to absorb into the juice, **the process took about 3 minutes, and with the help of a stirring spoon,** the powder was completely absorbed by the juice, **forming citrate salts of the freebase alkaloids for more efficient absorption in the body**. I read over my intentions again, reflected on them, asked the spirits of the four directions for protection on this journey, lit some incense, and drank the extract-containing juice. After drinking, **I set a timer for 20 minutes on my watch so I would know when to take the capsule containing the DMT Fumarate…**

… Eventually, the timer went off and **I promptly took the capsule containing 50mg DMT Fumarate.** Within 15 minutes, I was feeling the first alerts. A slight lethargy and softening of emotions. A slowing down…"

4. 1108, "Threshold Oral Experience Huasca Combo (Syrian Rue & M. tenuiflora)" December 31, 2009; retrieved from Erowid Experience Vaults. https://erowid.org/experiences/exp.php?ID=76862, retrieved December 31, 2009

From **webpage**

DOSE: T+ 0:00	160 mg	oral	Harmala Alkaloids	(powder / crystals)
T+ 0:35	580 mg	oral	Mimosa tenuiflora	(tea)
T+ 1:25	600 mg	oral	Mimosa tenuiflora	(tea)

From **webpage** "
1:00PM
I had previously **extracted the alkaloids from 2 ounces Syrian rue seeds yielding 1g of brownish crystals (which should be about 2/3 harmine HCl** and 1/3 harmaline HCl). **I weighed out 600mg of**

	extract and dissolved it in water. This was poured into 4 identical shot glasses, with the level on my glass slightly higher than my girlfriend's glass. **I estimate that I took 160mg**… 1:35PM The combined cups of 'tea' were then split by volume into 4 portions. C and A both took 125ml, I took 138ml, and my girlfriend took 87ml. This works out to 0.58g of MHRB personally consumed, for an **estimated 7mg of DMT,** based on the results of an extraction on the rest of the root bark…"
3. A pharmaceutical composition comprising: (a) N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and (b) harmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.	1. Intl. Pat. Doc. No. WO2019081764A1 "Combination product for the treatment of neurological and/or psychiatric disorders" (Published May 2, 2019) From **Page 18 lines 21-29** "Preferably, the compound described by **formula (I) is N,N-dimethyltryptamine**, N,N- diethyltryptamine, N,N-dipropyltryptamine, N,N-diisopropyltryptamine, 5-methoxy-N,N-dimethyltryptamine..." From **page 27 lines 22-33** "In a preferred embodiment, any of the aforementioned combination products may **further comprise a monoamine oxidase inhibitor which can boost the effectiveness of the compound** described by formula (I). **Preferably, the monoamine oxidase inhibitor is: a) a β-carboline such as harmine (CAS No. 442-51 -3)**, harmaline (CAS No. 304-21 -2), tetrahydroharmine (CAS No. 17019-01 -1), harmol (CAS No. 487-03-6), and/or harmalol (CAS No. 525-57-5), their salts and/or esters;… From **page 27 lines 35-37 to page 28 lines 1-5** "**In a preferred embodiment, the combination product is a mixture of the compound described by formula (I) and the 5-HT2A receptor antagonist, i.e. the combination product is a composition**. In an alternative embodiment, the compound described by formula (I) and the 5-HT2A receptor antagonist are **physically separated**. For example, **the compound described by formula (I) could be contained in one blister pack while the 5-HT2A receptor antagonist is contained within a separate blister pack or the compound described by formula (I) and the 5- HT2A receptor antagonist could be contained in the same pill but be physically separated by a barrier, such as a gelatin barrier.**" From **page 18 lines 10-14** "Rather than a complex mixture of natural compounds derived from vegetation, **the two active ingredients of the present invention may be substantially pure and may or may not be combined with pharmaceutically acceptable carrier and/or diluent** as well as other controlled substances. In a preferred embodiment, the compound described by formula (I) is substantially pure."

	2. SOUZA (2019) "Validation of an analytical method for the determination of the main ayahuasca active compounds and application to real ayahuasca samples from Brazil" Journal of Chromatography. 1124: 197-203 From abstract "**Ayahuasca is a brew prepared from the water decoction of two Amazonian plants**, which is legally used for religious, cultural or therapeutic activities. The potential use of ayahuasca as a natural or phytotherapeutic drug is directly linked to the action of its active compounds and their connection with the **therapeutic efficacy** of the beverage. In this context, the aim of the present study was to establish a selective, sensitive and reproducible analytical method for the **quantification of the main active ayahuasca compounds**. **Thirty-eight** samples from the state of São Paulo, Brazil, **were analyzed and the simultaneous quantifications of N,N-dimethyltryptamine (DMT)**, tetrahydroharmine (THH), **harmine (HME)** and harmaline (HML) were performed. This study enabled the development of a fast **validated analytical method with minimal matrix interference and high reproducibility for the tracing of active ayahuasca compound concentrations for the first time**. This method is important as an auxiliary tool for the study of active compound effects in biological responses using different multi-omic platforms." From **page 199** "In order to calculate linearity, three analytical curves with seven points each were prepared, varying analyte concentrations according to the intervals described in the Suppl. Table 2…**Based on the variance and linear regression, the linearity results were able to provide the concentration ranges for the determination of target analyte concentrations** [26,27]." From **page 200** **Table 2** Regression data for each ayahuasca analyte. Linearity (n = 21) / Concentration range DMT (1.5–15.0 mg/L) / THH (3.5–35.0 mg/L) / HME (6.0–60.0 mg/L) / HML (1.0–5.5 mg/L) r: 0.9956 / 0.9982 / 0.9966 / 0.9969 R^2: 0.9912 / 0.9963 / 0.9933 / 0.9939 Linear equation: y = 0.2644× + 0.4749 / y = 0.0925× + 0.1756 / y = 0.1798× + 1.282 / y = 0.1608× + 0.0766 Residual range: −0.16 to 0.23 / −0.07 to 0.18 / −0.33 to 0.50 / −0.029 to 0.032
4. The kit of parts according to claim 1 or the pharmaceutical composition of claim 3, wherein (a) is N,N-dimethyltryptamine fumarate and a pharmaceutically acceptable carrier.	16. SHROOMERY, "Re: Ayahuasca failure (Syrian Rue and MImosa) [Re: thoraxx]" March 19, 2016; retrieved from Shroomery. https://www.shroomery.org/forums/showflat.php/Number/23022449; retrieved March 19, 2016 From **webpage** "When using plain rue and root bark, you're throwing darts. If you wanna get serious, **order a gram of Harmine hcl** + Harmaline hcl, **and mix that with some DMT fumarate**. You can

dial in your dose more easily and it has always been effective that way for me and others. **I use about 200mg harmalas + 150mg dmt**."

From **webpage** "Aya is elusive. I struggled a lot to get a successful experience. **It came down to extracting the MAOI from caapi, and converting some DMT to the salt form, mixed together in 1 capsule down the hatch.**"

11. STRASSMAN (1994) "Dose-Response Study of N,N-Dimethyltryptamine in Humans" Archives of General Psychiatry. 51(2): 85-97

From **page 86** "**Dimethyltryptamine fumarate** was prepared by David E. Nichols, PhD, Purdue University, West Lafayette, Ind. Purity, determined by gas chromatography-mass spectrometry and high-performance liquid chromatography, was greater than 99.9%. It was prepared for **clinical administration** by the Inpatient Pharmacy of the University of New Mexico Hospital in vials containing 40 mg/mL."

3. INNEREXPLORER, "There Is Nothing To Be Afraid Of. Huasca Combo (B. caapi Extract & DMT Fumarate)" October 15, 2017; retrieved from Erowid Experience Vaults. https://erowid.org/experiences/exp.php?ID=108203, retrieved October 15, 2017

From **webpage**

DOSE: T+ 0:00		oral	Banisteriopsis caapi	(extract)
T+ 0:20	50 mg	oral	DMT	

From **webpage** "I have had several experiences with **Caapi extract (180 mg harmine** and 180 mg tetrahydroharmine) as well as with vine-only brews, but I have taken a pretty long break from both and have lately felt that this is **the best medicine for me** to work with."

From **webpage** "**After a few successful and very rewarding sessions with the Caapi extract**, **I thought it would be good to add in some DMT.** It just so happens that I had been planning on converting a gram of DMT freebase to **DMT Fumarate, which is the ideal form of DMT for oral** as well as IV/IM administration. ... **As such, the**

	best route seemed to be oral in combination with the Caapi extract. Experiment #1: **I recently experienced Caapi extract with 21mg DMT Fumarate (.32mg/kg)** which is a very very small dose, barely threshold. I did this purposely in order to ease my way into working with this powerful combination again. **The comeup on the Caapi extract was powerful as usual and I delayed taking the DMT an extra 20 minutes, taking it at t+0:40 instead of t+0:20.**.. In my next experiment, **I plan on increasing the dose to 35mg DMT (.54mg/kg) in combination with the Caapi extract**. I think this will be a bit more of a trip and will give me a better sense of my flight navigation skills. I am deliberately taking my time with this to get to know these medicines I am deliberately taking my time with this to get to know **these medicines as they work together** and how best to navigate the spaces they open up... Experiment #2: After careful research and reflection, I prepared to take my next journey with the **Caapi extract (which contains 180mg tetrahydroharmine and 180mg harmine) in combination with 50mg DMT Fumarate (.781mg/kg)**… … **I poured the Caapi extract into a glass of grapefruit juice** and allowed it to absorb into the juice, **the process took about 3 minutes, and with the help of a stirring spoon,** the powder was completely absorbed by the juice, **forming citrate salts of the freebase alkaloids for more efficient absorption in the body**. I read over my intentions again, reflected on them, asked the spirits of the four directions for protection on this journey, lit some incense, and drank the extract-containing juice. After drinking, **I set a timer for 20 minutes on my watch so I would know when to take the capsule containing the DMT Fumarate…** … Eventually, the timer went off and **I promptly took the capsule containing 50mg DMT Fumarate**…" 4. 1108, "Threshold Oral Experience Huasca Combo (Syrian Rue & M. tenuiflora)" December 31, 2009; retrieved from Erowid Experience

	Vaults. https://erowid.org/experiences/exp.php?ID=76862, retrieved December 31, 2009 From **webpage**  From **webpage** " 1:00PM I had previously **extracted the alkaloids from 2 ounces Syrian rue seeds yielding 1g of brownish crystals (which should be about 2/3 harmine HCl** and 1/3 harmaline HCl). **I weighed out 600mg of extract and dissolved it in water.** This was poured into 4 identical shot glasses, with the level on my glass slightly higher than my girlfriend's glass. **I estimate that I took 160mg**... 1:35PM The combined cups of 'tea' were then split by volume into 4 portions. C and A both took 125ml, I took 138ml, and my girlfriend took 87ml. This works out to 0.58g of MHRB personally consumed, for an **estimated 7mg of DMT,** based on the results of an extraction on the rest of the root bark..."
5. The kit of parts according to claim 1 or 4, or the pharmaceutical composition of claim 3 or 4, wherein (b) is harmine hydrochloride and a pharmaceutically acceptable carrier.	4. 1108, "Threshold Oral Experience Huasca Combo (Syrian Rue & M. tenuiflora)" December 31, 2009; retrieved from Erowid Experience Vaults. https://erowid.org/experiences/exp.php?ID=76862, retrieved December 31, 2009 From **webpage**  From **webpage** " 1:00PM I had previously **extracted the alkaloids from 2 ounces Syrian rue seeds yielding 1g of brownish crystals (which should be about 2/3 harmine HCl** and 1/3 harmaline HCl). **I weighed out 600mg of extract and dissolved it in water.** This was poured into 4 identical shot glasses, with the level on my glass slightly higher than my girlfriend's glass. **I estimate that I took 160mg**. The taste was a bit bitter and unpleasant, but bearable. I then weighed out 2 grams of mimosa hostilis root bark powder and placed it in a cup of boiling

	water. This was left to stand for a few minutes. We then began to filter out the powder and another cup of water was poured on the sludge that remained in the bottom of the cup. Filtering with coffee filters turned out to be a waste of time. 1:35PM The combined cups of 'tea' were then split by volume into 4 portions. C and A both took 125ml, I took 138ml, and my girlfriend took 87ml. This works out to 0.58g of MHRB personally consumed, for an **estimated 7mg of DMT,** based on the results of an extraction on the rest of the root bark…"
6. The kit of parts according to any one of claim 1, 4 or 5, or the kit of parts of any one of claim 3, 4 or 5, for use as a medicament.	3. INNEREXPLORER, "There Is Nothing To Be Afraid Of. Huasca Combo (B. caapi Extract & DMT Fumarate)" October 15, 2017; retrieved from Erowid Experience Vaults. https://erowid.org/experiences/exp.php?ID=108203, retrieved October 15, 2017 From **webpage**  From **webpage** "I have had several experiences with **Caapi extract (180 mg harmine** and 180 mg tetrahydroharmine) as well as with vine-only brews, but I have taken a pretty long break from both and have lately felt that this is **the best medicine for me** to work with." From **webpage** "**After a few successful and very rewarding sessions with the Caapi extract**, **I thought it would be good to add in some DMT.** It just so happens that I had been planning on converting a gram of DMT freebase to **DMT Fumarate, which is the ideal form of DMT for oral** as well as IV/IM administration. At first, I was drawn to the idea of IM administration but I realized that I would need to spend a good deal of time preparing the proper safety precautions in order to minimize error or accidental injury. **As such, the best route seemed to be oral in combination with the Caapi extract**. Experiment #1: **I recently experienced Caapi extract with 21mg DMT Fumarate (.32mg/kg)** which is a very very small dose, barely threshold. I did this purposely in order to ease my way into working with this powerful combination again. **The comeup on the Caapi extract was powerful**

	as usual and I delayed taking the DMT an extra 20 minutes, taking it at t+0:40 instead of t+0:20… In my next experiment, **I plan on increasing the dose to 35mg DMT (.54mg/kg) in combination with the Caapi extract**. I think this will be a bit more of a trip and will give me a better sense of my flight navigation skills. I am deliberately taking my time with this to get to know these medicines I am deliberately taking my time with this to get to know **these medicines as they work together** and how best to navigate the spaces they open up... Experiment #2: After careful research and reflection, I prepared to take my next journey with the **Caapi extract (which contains 180mg tetrahydroharmine and 180mg harmine) in combination with 50mg DMT Fumarate (.781mg/kg)**… … **I poured the Caapi extract into a glass of grapefruit juice** and allowed it to absorb into the juice, **the process took about 3 minutes, and with the help of a stirring spoon,** the powder was completely absorbed by the juice, **forming citrate salts of the freebase alkaloids for more efficient absorption in the body**. I read over my intentions again, reflected on them, asked the spirits of the four directions for protection on this journey, lit some incense, and drank the extract-containing juice. After drinking, **I set a timer for 20 minutes on my watch so I would know when to take the capsule containing the DMT Fumarate…** … Eventually, the timer went off and **I promptly took the capsule containing 50mg DMT Fumarate**…"
7. The kit of parts for use or the pharmaceutical composition for use according to claim 6, for use in treating a psychiatric, psychosomatic or somatic disorder.	5. OSORIO (2015) "Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report" Revista Brasileira de Psiquiatria. 37 (1): 13-20 From abstract "Objectives: **Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore have antidepressant actions.** This study sought to evaluate the effects of a single dose of AYA in six volunteers with a current depressive episode. Methods: Open-label trial conducted in an inpatient psychiatric unit.

	Results: **Statistically significant reductions of up to 82% in depressive scores were observed between baseline and 1, 7, and 21 days after AYA administration**, as measured on the Hamilton Rating Scale for Depression (HAM-D), the Montgomery-A˚ sberg Depression Rating Scale (MADRS), and the Anxious-Depression subscale of the Brief Psychiatric Rating Scale (BPRS)… Conclusions: **These results suggest that AYA has fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder."** From **page 19** "The findings of this preliminary study demonstrate the **potential antidepressant and anxiolytic effects of AYA**, effects that, importantly, have an earlier onset of action when compared to traditional antidepressants. These findings suggest that **AYA may represent a powerful new substance for the treatment of depressive and anxiety symptoms.** However, these results deserve careful analysis, given the inherent limitations of an uncontrolled, open-label study with a small sample size."
8. The kit of parts for use or the pharmaceutical composition for use according to claim 6 or 7, wherein the psychiatric disorder is depression, stress-related affective disorder, major depressive disorder, dysthymia, treatment-resistant depression, burnout, anxiety, post-traumatic stress disorder, addiction, eating disorder, or obsessive-compulsive disorder.	1. Intl. Pat. Doc. No. WO2019081764A1 "Combination product for the treatment of neurological and/or psychiatric disorders" (Published May 2, 2019) From "The term "**therapeutically effective amount refers to an amount of compound in a combination product which has a therapeutic effect** and which is able to **alleviate and/or cure a psychiatric and/or neurological disorder.** From "The term "**psychiatric disorder**" refers to a diagnosis by a mental health professional of a behavioral or mental pattern that may cause suffering or a poor ability to function in life. "Psychiatric disorders" may be persistent, relapsing and remitting, or occur as a single episode. In a preferred embodiment, the term "psychiatric disorder" refers to one or more disorders selected from the following: **alcohol and substance use disorders, anxiety disorders, panic disorder**, agoraphobia and other specific phobias, **social anxiety disorder, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder,** bipolar disorder, sleep and wake disorders, **depression, anorexia nervosa, binge eating disorder, bulimia nervosa,** psychosis, schizophrenia, autism spectrum disorders, developmental disorders, and personality disorders." From **Page 18 lines 21-29** "Preferably, the compound described by **formula (I) is N,N-dimethyltryptamine**, N,N- diethyltryptamine,

	N,N-dipropyltryptamine, N,N-diisopropyltryptamine, 5-methoxy-N,N-dimethyltryptamine..." From **page 27 lines 22-33** "In a preferred embodiment, any of the aforementioned combination products may **further comprise a monoamine oxidase inhibitor which can boost the effectiveness of the compound** described by formula (I). **Preferably, the monoamine oxidase inhibitor is: a) a β-carboline such as harmine (CAS No. 442-51 -3)**, harmaline (CAS No. 304-21 -2), tetrahydroharmine (CAS No. 17019-01 -1), harmol (CAS No. 487-03-6), and/or harmalol (CAS No. 525-57-5), their salts and/or esters; ... From **page 27 lines 35-37 to page 28 lines 1-5** "**In a preferred embodiment, the combination product is a mixture of the compound described by formula (I) and the 5-HT2A receptor antagonist, i.e. the combination product is a composition**. In an alternative embodiment, the compound described by formula (I) and the 5-HT2A receptor antagonist are **physically separated**. For example, **the compound described by formula (I) could be contained in one blister pack while the 5-HT2A receptor antagonist is contained within a separate blister pack or the compound described by formula (I) and the 5- HT2A receptor antagonist could be contained in the same pill but be physically separated by a barrier, such as a gelatin barrier.**" From **page 18 lines 10-14** "Rather than a complex mixture of natural compounds derived from vegetation, **the two active ingredients of the present invention may be substantially pure and may or may not be combined with pharmaceutically acceptable carrier and/or diluent** as well as other controlled substances. In a preferred embodiment, the compound described by formula (I) is substantially pure." 11. STRASSMAN (1994) "Dose-Response Study of N,N-Dimethyltryptamine in Humans" Archives of General Psychiatry. 51(2): 85-97 From **page 86** "**Dimethyltryptamine fumarate** was prepared by David E. Nichols, PhD, Purdue University, West Lafayette, Ind. Purity, determined by gas chromatography-mass spectrometry and high-performance liquid chromatography, was greater than 99.9%. It was prepared for **clinical administration** by the Inpatient Pharmacy of the University of New Mexico Hospital in vials containing 40 mg/mL." From **page 88**

Demographic Characteristics of Subjects*

Subject No./ Age, y/Sex	Occupation	Axis I Diagnoses	Marital Status	Family Psychiatric History	Times Used: Marijuana	Cocaine, Amphetamines	Hallucinogens	Methylene dioxymethamphetamine
1/45/M	Construction worker	None	Divorced ×2, married	None	10-20	0	10-20	10
2/39/F	Psychologist	None	Divorced ×2, married	Father, depression, chronic; eating disorder?; mother, "hysterical"	100s	50-100	>50	75-100
3/38/M	Physician	Major depression, resolved; cannabis dependence, partial remission	Divorced ×1	Father, depression (taking amitriptyline hydrochloride)	1000s	3	50	1
4/45/M	Psychologist	Adjustment disorder, depressed	Divorced ×3	Brother, adjustment disorder, mixed	>400	15	30	10-15
5/34/M	Graduate student	Alcohol dependence, in remission; cannabis abuse, in remission	Never married	Brother, major depression	1000s	20-25	20-30	1
6/37/M	Resident physician	Major depression, resolved	Never married	None	1000s	15-20	50-60	0
7/42/M	City administrator	None	Divorced ×1, married	None	100s	<10	>100	5-10
8/36/M	Drug dealer	Cannabis dependence, in remission; cocaine dependence, in remission; stimulant abuse, in remission	Divorced ×1, married	Father, alcohol abuse	1000s	100s	>200	5-10
9/46/M	Owner of large business	Adjustment disorder, depressed, resolved; alcohol abuse, in remission	Divorced ×1	Mother, alcohol abuse; father, alcohol abuse	100s	50-100	6	0
10/45/M	Restaurant manager, writer	Cocaine dependence, in remission; alcohol abuse, in remission; major depression, resolved; depressive disorder, NOS, resolved	Divorced ×3	Father, alcohol abuse	100s	100	>100	10-12
11/38/M	Physician	Prolonged (18-mo) grief reaction vs major depression, resolved	Divorced ×2	Mother, major depression; father, alcohol abuse	50	3	75-100	8
12/50/M	Counselor	None	Divorced ×2, married	Alcohol abuse	100s	15-20	10	2

*NOS indicates not otherwise specified. Subject 11 suffered a major depression during the study and was withdrawn before completing it. His data are included for illustrative purposes.

From **page 86** "There was a high incidence of prior **major depression in the group**. Only one subject was suffering any current Axis I disorder; this was an **adjustment disorder** resulting from an impending divorce. There also was a high incidence of first-degree relatives suffering from **depression and/or alcohol abuse**. The number of exposures to hallucinogens ranged from six to "hundreds." Two subjects described a history of **cocaine dependence/abuse**, currently in remission; the remainder had little or no exposure to cocaine or amphetamines. Not all subjects had used marijuana equally, although all had some experience with it."

5. OSORIO (2015) "Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report" Revista Brasileira de Psiquiatria. 37 (1): 13-20

From abstract "Objectives: **Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore have antidepressant actions.** This study sought to evaluate the effects of a single dose of AYA in six volunteers with a current depressive episode.

	Methods: Open-label trial conducted in an inpatient psychiatric unit. Results: **Statistically significant reductions of up to 82% in depressive scores were observed between baseline and 1, 7, and 21 days after AYA administration**, as measured on the Hamilton Rating Scale for Depression (HAM-D), the Montgomery-A˚ sberg Depression Rating Scale (MADRS), and the Anxious-Depression subscale of the Brief Psychiatric Rating Scale (BPRS)... Conclusions: **These results suggest that AYA has fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder**." From **page 19** "The findings of this preliminary study demonstrate the **potential antidepressant and anxiolytic effects of AYA**, effects that, importantly, have an earlier onset of action when compared to traditional antidepressants. These findings suggest that **AYA may represent a powerful new substance for the treatment of depressive and anxiety symptoms.** However, these results deserve careful analysis, given the inherent limitations of an uncontrolled, open-label study with a small sample size." 6. NUNES (2016) "Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans" Journal of Psychoactive Drugs. 48(3): 195-205 From **abstract** "Recently, **the anti-addictive potential of ayahuasca, a dimethyltryptamine(DMT)- and β-carboline-rich hallucinogenic beverage** traditionally used by indigenous groups of the Northwest Amazon and currently by syncretic churches worldwide, has received increased attention. To better evaluate this topic, we performed a systematic literature review using the PubMed database to find quantitative studies (using statistical analysis) that **assessed the effects of ayahuasca or its components in drug related symptoms or disorders**. We found five animal studies (using harmaline, **harmine**, or ayahuasca) and five observational studies of regular ayahuasca consumers. **All animal studies showed improvement of biochemical or behavioral parameters related to drug-induced disorders**. Of the five human studies, **four reported significant reductions of dependence symptoms or substance use, while one did not report significant results.** The mechanisms responsible for the anti-addictive

	properties of ayahuasca and its alkaloids are not clarified, apparently involving both peripheral MAO-A inhibition by the **β-carbolines and central agonism of DMT** at 5-HT2A receptors expressed in brain regions related to the **regulation of mood and emotions**. Although results are promising, controlled studies are needed to replicate these preliminary findings." 7. INSERRA (2018) "Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process" Frontier in Pharmacology. 9: 330 From **page 1** "Ayahuasca ingestion modulates brain activity, neurotransmission, gene expression and epigenetic regulation. **N,N-Dimethyltryptamine (DMT, one of the alkaloids in Ayahuasca)** activates sigma 1 receptor (SIGMAR1) and others. SIGMAR1 is a multi-faceted stress responsive receptor which promotes cell survival, neuroprotection, neuroplasticity, and neuroimmunomodulation. **Simultaneously, monoamine oxidase inhibitors (MAOIs) also present in Ayahuasca prevent the degradation of DMT.** One peculiarity of SIGMAR1 activation and MAOI activity is the reversal of mnemonic deficits in preclinical models. **Since traumatic memories in post-traumatic stress disorder (PTSD) are often characterised by "repression" and PTSD patients ingesting Ayahuasca report the retrieval of such memories**, it cannot be excluded that DMT-mediated SIGMAR1 activation and the concomitant MAOIs effects during Ayahuasca ingestion might mediate such "anti-amnesic" process…" 8. RENELLI (2020) "An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders" Eating and Weight Disorders. 25(2): 437-444 From **abstract** "Purpose Ayahuasca is a traditional Amazonian medicine that is currently being researched for its potential in treating a variety of mental disorders. This article reports on exploratory qualitative research relating to **participant experiences with ceremonial ayahuasca drinking and conventional treatment for eating disorders (EDs). It also explores the potential for ayahuasca as an adjunctive ED treatment.**

	Results Participant reports were organized with key themes including that ayahuasca: led to rapid reductions in ED thoughts and symptoms; allowed for the healing of the perceived root of the ED; helped to process painful feelings and memories; supported the internalization of greater self-love and self-acceptance; and catalyzed spiritual elements of healing. Conclusions **The results suggest that ayahuasca may have potential as a valuable therapeutic tool,** and further research—including carefully controlled clinical trials—is warranted."
9. The kit of parts for use or the pharmaceutical composition for use according to any one of claims 6 to 8, wherein (a) and (b) are not to be administered perorally.	1. Intl. Pat. Doc. No. WO2019081764A1 "Combination product for the treatment of neurological and/or psychiatric disorders" (Published May 2, 2019) From **page 33 lines 25-29** "In a preferred embodiment, **the combination product is prepared for** oral, sublingual, buccal, **intranasal**, i**ntravenous, intramuscular, subcutaneous, rectal, transdermal, topical and/or inhalation-mediated administration routes**, preferably oral, sublingual, inhalation-mediated and/or intranasal routes."
10. The kit of parts for use or the pharmaceutical composition for use according to any one of claims 6 to 9, wherein (a) and (b) are to be administered simultaneously or sequentially.	1. Intl. Pat. Doc. No. WO2019081764A1 "Combination product for the treatment of neurological and/or psychiatric disorders" (Published May 2, 2019) From **Page 18 lines 21-29** "Preferably, the compound described by **formula (I) is N,N-dimethyltryptamine**, N,N- diethyltryptamine, N,N-dipropyltryptamine, N,N-diisopropyltryptamine, 5-methoxy-N,N-dimethyltryptamine..." From **page 27 lines 22-33** "In a preferred embodiment, any of the aforementioned combination products may **further comprise a monoamine oxidase inhibitor which can boost the effectiveness of the compound** described by formula (I). **Preferably, the monoamine oxidase inhibitor is: a) a β-carboline such as harmine (CAS No. 442-51 -3)**, harmaline (CAS No. 304-21 -2), tetrahydroharmine (CAS No. 17019-01 -1), harmol (CAS No. 487-03-6), and/or harmalol (CAS No. 525-57-5), their salts and/or esters;… From **page 27 lines 35-37 to page 28 lines 1-5** "**In a preferred embodiment, the combination product is a mixture of the compound described by formula (I) and the 5-HT2A receptor antagonist, i.e. the combination product is a composition**. In an alternative embodiment, the compound described by formula (I) and the 5-HT2A receptor antagonist are **physically separated**. For example, **the compound described by formula (I) could be contained in one blister pack while the 5-HT2A receptor**

	antagonist is contained within a separate blister pack or the compound described by formula (I) and the 5- HT2A receptor antagonist could be contained in the same pill but be physically separated by a barrier, such as a gelatin barrier." 3. INNEREXPLORER, "There Is Nothing To Be Afraid Of. Huasca Combo (B. caapi Extract & DMT Fumarate)" October 15, 2017; retrieved from Erowid Experience Vaults. https://erowid.org/experiences/exp.php?ID=108203, retrieved October 15, 2017 From **webpage**  From **webpage** " Experiment #1: **I recently experienced Caapi extract with 21mg DMT Fumarate (.32mg/kg)** which is a very very small dose, barely threshold. I did this purposely in order to ease my way into working with this powerful combination again. **The comeup on the Caapi extract was powerful as usual and I delayed taking the DMT an extra 20 minutes, taking it at t+0:40 instead of t+0:20.** I don't think that would have reduced the efficacy of the DMT at all, but rather it was the very low dose of DMT that led to very little effects..."
11. The kit of parts for use or the pharmaceutical composition for use according to any one of claims 6 to 10, wherein (a) is to be administered intranasally.	1. Intl. Pat. Doc. No. WO2019081764A1 "Combination product for the treatment of neurological and/or psychiatric disorders" (Published May 2, 2019) From **page 33 lines 25-29** "In a preferred embodiment, **the combination product is prepared for** oral, sublingual, buccal, **intranasal**, intravenous, intramuscular, subcutaneous, rectal, transdermal, topical and/or inhalation-mediated administration routes, preferably oral, sublingual, inhalation-mediated and/or intranasal routes." From **Page 18 lines 21-29** "Preferably, the compound described by **formula (I) is N,N-dimethyltryptamine**, N,N- diethyltryptamine, N,N-dipropyltryptamine, N,N-diisopropyltryptamine, 5-methoxy-N,N-dimethyltryptamine..." From **page 27 lines 22-33** "In a preferred embodiment, any of the aforementioned combination products may **further comprise a**

	monoamine oxidase inhibitor which can boost the effectiveness of the compound described by formula (I). **Preferably, the monoamine oxidase inhibitor is: a) a β-carboline such as harmine (CAS No. 442-51 -3)**, harmaline (CAS No. 304-21 -2), tetrahydroharmine (CAS No. 17019-01 -1), harmol (CAS No. 487-03-6), and/or harmalol (CAS No. 525-57-5), their salts and/or esters...
12. The kit of parts for use or the pharmaceutical composition for use according to any one of claims 6 to 11, wherein (a) is to be administered in a dose of between 10 mg to 100 mg of N,N-dimethyltryptamine per administration, preferably in an incremental manner over a period of time of between 60 to 180 minutes.	14. GALLIMORE (2016) "A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience" Frontiers in Pharmacology. 7:1-11 From **page 6** "To examine the possibility of effect site concentration overshoot, we performed simulations using the Gouzoulis-Mayfrank infusion protocol: 0.3 mg/kg bolus, followed by **an infusion beginning at 1.5 min, at a rate of 0.02 mg/kg/min over 84 min**. **Figure 4 shows the expected effect site concentration over this infusion period for a 75 kg subject**. The initial bolus produces an effect site concentration of 80 ng/ml; i.e., a breakthrough dose. Once the infusion begins, however, **the concentration rises steadily, and reaches 150 ng/ml by the end of the session**. This is a very high concentration and is certain to produce extremely intense effects in almost all individuals. Using our PK model, **we developed an infusion protocol that maintains an effect site concentration of ∼100 ng/ml in a 75 kg subject (Figure 5)**. An initial bolus of 25 mg infused over 30 s rapidly brings the effect site concentration to just over 100 ng/ml. Although the plasma concentration spikes at over 200 ng/ml, the desired effect site concentration is reached smoothly with very little overshoot. The infusion begins at 2 min at a rate of 4.2 mg/min. The infusion is updated every min, and decreases according to the peripheral transfer rate decay (the exponential term in the RT equation). Steady state does not occur until after 20 min of infusion, after which **a constant maintenance infusion rate of 0.93 mg/min is employed**."

From **page 7** “



FIGURE 4 | Simulated time course of plasma and effect site DMT concentration using the (Gouzoulis-Mayfrank et al., 2005) protocol.

”

From **page 8** “



FIGURE 5 | Simulated time course of infusion protocol designed to reach and maintain effect site concentration of ~100 ng/ml.

”

11. STRASSMAN (1994) “Dose-Response Study of N,N-Dimethyltryptamine in Humans” Archives of General Psychiatry. 51(2): 85-97

From **abstract** “Methods: **Dimethyltryptamine**, an endogenous mammalian hallucinogen and drug of abuse, was administered **intravenously at 0.05, 0.1, 0.2, and 0.4 mg/kg** to 11 experienced hallucinogen users, in a double-blind, saline placebo controlled, randomized design. Treatments were separated by at least 1 week.”

13. U.S. Pat. App. Doc. No. US2020/0179349A1 “Methods Of Treating Food Allergy Conditions” (Published June 11, 2020)

	From **[0076]** "In some embodiments, **DMT** may be administered at or above a threshold dose, including but not limited to e.g., a threshold dose at or above **10 milligrams (mg)**, including e.g., where smoked delivery is employed. In some instances, a threshold dose of DMT may range from **2 mg to 10 mg**, including e.g., by smoked delivery. In some embodiments, DMT may be administered as a light dose, including but not limited to e.g., a light dose ranging from **10 mg to 20 mg**, including e.g., by smoked delivery. In some embodiments, DMT may be administered as a common dose, including but not limited to e.g., a common dose ranging from **20 mg to 40 mg**, including e.g., by smoked delivery. In some embodiments, DMT may be administered as a strong dose, including but not limited to e.g., a strong dose ranging from **40 mg to 60 mg**, including e.g., by smoked delivery. In some embodiments, DMT may be administered as a heavy dose, including but not limited to e.g., where **DMT is administered at a dose above 60 mg**, e.g., by smoked delivery." From **[0024]** "In some instances, an amount of **a psychedelic agent administered** to a subject may be in the milligram range, including but not limited to e.g., from **1 mg to 1000 mg, from 2 mg to 1000 mg, from 3 mg to 1000 mg, from 4 mg to 1000 mg, from 5 mg to 1000 mg, from 10 mg to 1000 mg, from 15 mg to 1000 mg, from 20 mg to 1000 mg, from 30 mg to 1000 mg, from 40 mg to 1000 mg, from 50 mg to 1000 mg, from 75 mg to 1000 mg**, from 100 mg to 1000 mg, from 150 mg to 1000 mg, from 200 mg to 1000 mg, from 300 mg to 1000 mg, from 400 mg to 1000 mg, from 500 mg to 1000 mg, from 600 mg to 1000 mg, from 700 mg to 1000 mg, from 800 mg to 1000 mg, from 900 mg to 1000 mg, from 1 mg to 900 mg, from 1 mg to 800 mg, from 1 mg to 700 mg, from 1 mg to 600 mg, from 1 mg to 500 mg, from 1 mg to 450 mg, from 1 mg to 400 mg, from 1 mg to 350 mg, from 1 mg to 300 mg, from 1 mg to 250 mg, from 1 mg to 200 mg, from 1 mg to 175 mg, from 1 mg to 150 mg, from 1 mg to 125 mg, from **1 mg to 100 mg**, etc." From **[0074]** "Useful **tryptamine psychedelic agents** include but are not limited to e.g., diethyltryptamine (DET), **N,N-dimethyltryptamine (DMT)**…etc" From **[0161]** "Any convenient and appropriate route of administration may be employed in **delivering a psychedelic agent** to a subject, including but not limited to e.g., **oral, inhalation** (e.g., smoked, vaporized, etc.), **intra-arteria injection/infusion, intravenous injection/infusion**, intramuscular injection, as well as topical routes, including e.g., transdermal, transmucosal (e.g., sublingual,

	insufflation, and/or **buccal**), and the like. In some instances, a delivery device configured for delivering the one or more psychedelic agents according to any desired and appropriate route of delivery may be employed." 3. INNEREXPLORER, "There Is Nothing To Be Afraid Of. Huasca Combo (B. caapi Extract & DMT Fumarate)" October 15, 2017; retrieved from Erowid Experience Vaults. https://erowid.org/experiences/exp.php?ID=108203, retrieved October 15, 2017 From **webpage**  DOSE: T+ 0:00 — oral — Banisteriopsis caapi — (extract) T+ 0:20 — 50 mg — oral — DMT From **webpage** "I have had several experiences with **Caapi extract (180 mg harmine** and 180 mg tetrahydroharmine) as well as with vine-only brews, but I have taken a pretty long break from both and have lately felt that this is **the best medicine for me** to work with." From **webpage** "**After a few successful and very rewarding sessions with the Caapi extract**, **I thought it would be good to add in some DMT.** It just so happens that I had been planning on converting a gram of DMT freebase to **DMT Fumarate, which is the ideal form of DMT for oral** as well as IV/IM administration. At first, I was drawn to the idea of IM administration but I realized that I would need to spend a good deal of time preparing the proper safety precautions in order to minimize error or accidental injury. **As such, the best route seemed to be oral in combination with the Caapi extract**. Experiment #1: **I recently experienced Caapi extract with 21mg DMT Fumarate (.32mg/kg)** which is a very very small dose, barely threshold. I did this purposely in order to ease my way into working with this powerful combination again. **The comeup on the Caapi extract was powerful as usual and I delayed taking the DMT an extra 20 minutes, taking it at t+0:40 instead of t+0:20.** I don't think that would have reduced the efficacy of the DMT at all, but rather it was the very low dose of DMT that led to very little effects. It was interesting that once I felt the DMT come on I felt very very tired and almost felt like I slept through the whole experience, though the two purges that I had

	were very emotionally based and were centered around purging negative thought patterns I have kept inside. In my next experiment, **I plan on increasing the dose to 35mg DMT (.54mg/kg) in combination with the Caapi extract**. I think this will be a bit more of a trip and will give me a better sense of my flight navigation skills. I am deliberately taking my time with this to get to know these medicines I am deliberately taking my time with this to get to know **these medicines as they work together** and how best to navigate the spaces they open up. This is how the shamans came to understand their work with the plants. Gradual increases in doses and getting to know the spirits of these medicines. Experiment #2: After careful research and reflection, I prepared to take my next journey with the **Caapi extract (which contains 180mg tetrahydroharmine and 180mg harmine) in combination with 50mg DMT Fumarate (.781mg/kg)**… … **I poured the Caapi extract into a glass of grapefruit juice** and allowed it to absorb into the juice, **the process took about 3 minutes, and with the help of a stirring spoon,** the powder was completely absorbed by the juice, **forming citrate salts of the freebase alkaloids for more efficient absorption in the body**. I read over my intentions again, reflected on them, asked the spirits of the four directions for protection on this journey, lit some incense, and drank the extract-containing juice. After drinking, **I set a timer for 20 minutes on my watch so I would know when to take the capsule containing the DMT Fumarate…** … Eventually, the timer went off and **I promptly took the capsule containing 50mg DMT Fumarate.** Within 15 minutes, I was feeling the first alerts. A slight lethargy and softening of emotions…" 12. EROWID, "DMT Dosage" February 21, 2015; retrieved from Erowid. https://erowid.org/chemicals/dmt/dmt_dose.shtml, retrieved February 21, 2015 From **webpage** "

	 ",
13. The kit of parts or the pharmaceutical composition for use according to any one of claims 6 to 12, wherein (b) is to be administered buccally and/or sublingually.	1. Intl. Pat. Doc. No. WO2019081764A1 "Combination product for the treatment of neurological and/or psychiatric disorders" (Published May 2, 2019) From **page 33 lines 25-29** "In a preferred embodiment, **the combination product is prepared for** oral, sublingual, buccal, intranasal, intravenous, intramuscular, subcutaneous, rectal, transdermal, topical and/or inhalation-mediated administration routes, preferably oral, **sublingual**, inhalation-mediated and/or intranasal **routes**." From **Page 18 lines 21-29** "Preferably, the compound described by **formula (I) is N,N-dimethyltryptamine**, N,N- diethyltryptamine, N,N-dipropyltryptamine, N,N-diisopropyltryptamine, 5-methoxy-N,N-dimethyltryptamine..." From **page 27 lines 22-33** "In a preferred embodiment, any of the aforementioned combination products may **further comprise a monoamine oxidase inhibitor which can boost the effectiveness of the compound** described by formula (I). **Preferably, the monoamine oxidase inhibitor is: a) a β-carboline such as harmine (CAS No. 442-51 -3)**, harmaline (CAS No. 304-21 -2), tetrahydroharmine (CAS No. 17019-01 -1), harmol (CAS No. 487-03-6), and/or harmalol (CAS No. 525-57-5), their salts and/or esters… From **page 27 lines 35-37 to page 28 lines 1-5** "**In a preferred embodiment, the combination product is a mixture of the compound described by formula (I) and the 5-HT2A receptor antagonist, i.e. the combination product is a composition**. In an alternative embodiment, the compound described by formula (I) and the 5-HT2A receptor antagonist are **physically separated**. For example, **the compound described by formula (I) could be contained in one blister pack while the 5-HT2A receptor antagonist is contained within a separate blister pack or the compound described by formula (I) and the 5- HT2A receptor antagonist could be contained in the same pill but be physically separated by a barrier, such as a gelatin barrier.**"

	From **page 18 lines 10-14** "Rather than a complex mixture of natural compounds derived from vegetation, **the two active ingredients of the present invention may be substantially pure and may or may not be combined with pharmaceutically acceptable carrier and/or diluent** as well as other controlled substances. In a preferred embodiment, the compound described by formula (I) is substantially pure."
14. The kit of parts for use or the pharmaceutical composition for use according to any one of claims 6 to 13, wherein (b) is to be administered in a dose of between 75 mg to 300 mg of harmine per administration.	15. EROWID, "Tihkal The Continuation Alexander & Ann Shulgin #14. HARMINE b-CARBOLINE, 7-METHOXY; 7-METHOXY-b-CARBOLINE; BANISTERINE; YAGEINE; TELEPATHINE; LEUCOHARMINE" February 21, 2015; retrieved from Erowid. https://erowid.org/library/books_online/tihkal/tihkal14.shtml, retrieved February 21, 2015 From **webpage** "… As with harmaline, a number of drug combinations have been studied using harmine as the potential deaminase inhibitor. This is, after all, much closer to the basic structure of **ayahuasca,** where the plant **Banisteriopsis caapi** is the native inhibitory component, and it contains much more **harmine** than harmaline**.** In measured experiments, **the use of harmine in the 140 to 190 milligram range, administered with 35 to 40 milligrams DMT**, produced unmistakable effects lasting from one to three hours. Trials with smaller amounts, **with 120 to 140 milligrams of harmine and 30 milligrams of DMT** produced no signs of central activity at all. Harmine apparently is an effective, although modest, **promoter of oral activity of DMT**. At least this occurs at levels where it itself is substantially without action, so here it may truly be a facilitator rather than a participant." From **webpage** "(**with 140 mg, orally**) "There was no stimulation, no suggestion of entheogenic response, perhaps a little bit of sedation which was still evident several hours later. It was sufficiently mild as to make me forget I had ingested anything." (**with 150-200 mg, i.v. [clinical distillation of Pennes and Hoch]**) "With this route, 5 of 11 subjects reported visual hallucinations of varying degrees of complexity and organization. Bradycardia and hypotension occurred with all doses of intravenous harmine despite a **20 to 30 minute injection time, thereby limiting maximum dosage to 300.0 mg.** Recovery occurred in about 30 minutes. The drug was hallucinogenic by **oral or subcutaneous routes**."

(with 300 mg, sublingually) "I found myself pleasantly relaxed and withdrawn from my environment. There was a slightly diminished capacity to concentrate."…"

3. INNEREXPLORER, "There Is Nothing To Be Afraid Of. Huasca Combo (B. caapi Extract & DMT Fumarate)" October 15, 2017; retrieved from Erowid Experience Vaults. https://erowid.org/experiences/exp.php?ID=108203, retrieved October 15, 2017

From **webpage**

DOSE: T+ 0:00		oral	Banisteriopsis caapi	(extract)
T+ 0:20	50 mg	oral	DMT	

From **webpage** "I have had several experiences with **Caapi extract (180 mg harmine** and 180 mg tetrahydroharmine) as well as with vine-only brews, but I have taken a pretty long break from both and have lately felt that this is **the best medicine for me** to work with."

From **webpage** "**After a few successful and very rewarding sessions with the Caapi extract**, **I thought it would be good to add in some DMT.** It just so happens that I had been planning on converting a gram of DMT freebase to **DMT Fumarate, which is the ideal form of DMT for oral** as well as IV/IM administration. At first, I was drawn to the idea of IM administration but I realized that I would need to spend a good deal of time preparing the proper safety precautions in order to minimize error or accidental injury. **As such, the best route seemed to be oral in combination with the Caapi extract**.

Experiment #1:

I recently experienced Caapi extract with 21mg DMT Fumarate (.32mg/kg) which is a very very small dose, barely threshold. I did this purposely in order to ease my way into working with this powerful combination again. **The comeup on the Caapi extract was powerful as usual and I delayed taking the DMT an extra 20 minutes, taking it at t+0:40 instead of t+0:20.** I don't think that would have reduced the efficacy of the DMT at all, but rather it was the very low dose of DMT that led to very little effects...

In my next experiment, **I plan on increasing the dose to 35mg DMT (.54mg/kg) in combination with the Caapi extract**... I am

	deliberately taking my time with this to get to know these medicines I am deliberately taking my time with this to get to know **these medicines as they work together** and how best to navigate the spaces they open up… Experiment #2: After careful research and reflection, I prepared to take my next journey with the **Caapi extract (which contains 180mg tetrahydroharmine and 180mg harmine) in combination with 50mg DMT Fumarate (.781mg/kg)**… … **I poured the Caapi extract into a glass of grapefruit juice** and allowed it to absorb into the juice, **the process took about 3 minutes, and with the help of a stirring spoon,** the powder was completely absorbed by the juice, **forming citrate salts of the freebase alkaloids for more efficient absorption in the body**. I read over my intentions again, reflected on them, asked the spirits of the four directions for protection on this journey, lit some incense, and drank the extract-containing juice. After drinking, **I set a timer for 20 minutes on my watch so I would know when to take the capsule containing the DMT Fumarate…** … Eventually, the timer went off and **I promptly took the capsule containing 50mg DMT Fumarate**…"
15. The kit of parts for use or the pharmaceutical composition for use according to any one of claims 6 to 14, wherein the administration of (b) is to be followed by the administration of (a).	3. INNEREXPLORER, "There Is Nothing To Be Afraid Of. Huasca Combo (B. caapi Extract & DMT Fumarate)" October 15, 2017; retrieved from Erowid Experience Vaults. https://erowid.org/experiences/exp.php?ID=108203, retrieved October 15, 2017 From **webpage**  From **webpage** "I have had several experiences with **Caapi extract (180 mg harmine** and 180 mg tetrahydroharmine) as well as with vine-only brews, but I have taken a pretty long break from both and have lately felt that this is **the best medicine for me** to work with." From **webpage** "**After a few successful and very rewarding sessions with the Caapi extract**, **I thought it would be good to add in some**

	DMT. It just so happens that I had been planning on converting a gram of DMT freebase to **DMT Fumarate, which is the ideal form of DMT for oral** as well as IV/IM administration. At first, I was drawn to the idea of IM administration but I realized that I would need to spend a good deal of time preparing the proper safety precautions in order to minimize error or accidental injury. **As such, the best route seemed to be oral in combination with the Caapi extract**. Experiment #1: **I recently experienced Caapi extract with 21mg DMT Fumarate (.32mg/kg)** which is a very very small dose, barely threshold. I did this purposely in order to ease my way into working with this powerful combination again. **The comeup on the Caapi extract was powerful as usual and I delayed taking the DMT an extra 20 minutes, taking it at t+0:40 instead of t+0:20.**.. In my next experiment, **I plan on increasing the dose to 35mg DMT (.54mg/kg) in combination with the Caapi extract**. I think this will be a bit more of a trip and will give me a better sense of my flight navigation skills. I am deliberately taking my time with this to get to know these medicines I am deliberately taking my time with this to get to know **these medicines as they work together** and how best to navigate the spaces they open up. This is how the shamans came to understand their work with the plants. Gradual increases in doses and getting to know the spirits of these medicines. Experiment #2: After careful research and reflection, I prepared to take my next journey with the **Caapi extract (which contains 180mg tetrahydroharmine and 180mg harmine) in combination with 50mg DMT Fumarate (.781mg/kg)…** … **I poured the Caapi extract into a glass of grapefruit juice** and allowed it to absorb into the juice, **the process took about 3 minutes, and with the help of a stirring spoon,** the powder was completely absorbed by the juice, **forming citrate salts of the freebase alkaloids for more efficient absorption in the body**. I read over my intentions again, reflected on them, asked the spirits of the four directions for protection on this journey, lit some incense, and drank the extract-containing juice. After drinking, **I set a timer for 20 minutes on my watch so I would know when to take the capsule containing the DMT Fumarate…**

	… Eventually, the timer went off and **I promptly took the capsule containing 50mg DMT Fumarate**…"

UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
18/012,122	**11/20/2023 03:23:44 PM Z ET**	

Title of Invention

Application Information

APPLICATION TYPE		PATENT #	
CONFIRMATION #		FILED BY	Sisi Li
PATENT CENTER #	63323001	FILING DATE	12/21/2022
CUSTOMER #	–	FIRST NAMED INVENTOR	
INTL. APPLICATION #	-	INTL. FILING DATE	-
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	-

Documents

TOTAL DOCUMENTS: 23

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
third-party-preissuance-submission.pdf		3	Third-Party Submission Under 37 CFR 1.290	79 KB
Concise-description-generated.pdf		2	Concise Description of Relevance	40 KB
Third-party-notification-request.pdf		1	Request for Notification of Non-compliant Third-Party Submission	14 KB
Claims_Chart.pdf		32	-	1034 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB

Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
1_WO2019081764A1.pdf		66	-	4430 KB
1_WO2019081764A1-FOR.pdf	(1-66)	66	Foreign Reference	4430 KB
2_SOUZA.pdf		7	-	944 KB
2_SOUZA-NPL.pdf	(1-7)	7	Non Patent Literature	915 KB
3_INNEREXPLORER.pdf		3	-	481 KB
3_INNEREXPLORER-NPL.pdf	(1-3)	3	Non Patent Literature	473 KB

4_1108.pdf		2	-	333 KB
4_1108-NPL.pdf	(1-2)	2	Non Patent Literature	326 KB
5_OSORIO.pdf		8	-	194 KB
5_OSORIO-NPL.pdf	(1-8)	8	Non Patent Literature	195 KB
6_NUNES.pdf		12	-	1274 KB
6_NUNES-NPL.pdf	(1-12)	12	Non Patent Literature	1260 KB
7_INSERRA.pdf		13	-	363 KB
7_INSERRA-NPL.pdf	(1-13)	13	Non Patent Literature	314 KB
8_RENELLI.pdf		8	-	756 KB
8_RENELLI-NPL.pdf	(1-8)	8	Non Patent Literature	689 KB
9_CAMERON.pdf		14	-	1403 KB
9_CAMERON-NPL.pdf	(1-14)	14	Non Patent Literature	1454 KB
10_DMTNEXUS.pdf		1	-	257 KB
10_DMTNEXUS-NPL.pdf	(1-1)	1	Non Patent Literature	250 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
third-party-preissuance-submission.pdf	795679B50D53857640E4905E7EC41A8740C5CFA0F51AC3F09E7212F95EA9DD91EB615760464410ED5E31B84FB998D76025371E685504025AAFA54F9E26834088
Concise-description-	91B07897D5FF45B809E8B8C5C89F1051828BAB913F41A726D3

generated.pdf	AE10B732BC58D36A24BA21305C1DE964FE0E521E4557B10BE5B9A0B47CFB29D5B6A0EBC74A31DD
Third-party-notification-request.pdf	A46B4314DD16642C1E0E903A073D6EF515F011324D75BF578FCD82D82B6EB054A55A42F9537CFD84A8A287B1A59A7224FBE2600BEC1C535882E0195C0FE7B938
Claims_Chart.pdf	DE5FC0433383B228748D1915919CF0440A119EBE1AF83C27571A2C375A4563C4FEC708EF508D1D7BD648B96EC9292858C4B38057FE3A27AE2B574B799E97A688
Claims_Chart-3P.RELEVANCE.pdf	6389D73211F943A9A08C0E89F1D95467FD7A5251B96900C4E332D1C2EE426573DF27A73432EAB6729E53C5A8D6D529AD6FFADE38D353FBC9C12074EB6F2A1AA4
Claims_Chart-3P.RELEVANCE.pdf	F77D2346543A4ADA431E05D94492D61275E1DB17D214847A26FEA4DE25DC4F44043FC095F3AC51DFCE64A6A6C2CD9F9E6596E177F3D8D1B0CA8550C294814A9C
Claims_Chart-3P.RELEVANCE.pdf	9FA9AC9B2A40CDEC7AB3D8570608076C6F344D0F4710E6F4E7A0B728AA9C1B8A5FE2E263B89218EF4B71CAE9F7B8AA25902AD569DAB962F052F4FC42E035FA7D
Claims_Chart-3P.RELEVANCE.pdf	C0D8EB6B8DE654F1C9D4C1BD10EE27559BCB23D91EC5243A48C6CCBE71BBD26C9BD3B514133237318C76484E18DC35EABB897AD1561D6B1A73052503A32B3FBD
Claims_Chart-3P.RELEVANCE.pdf	BB18AD03A9F6A9BE18CD94975201682CF5C55B36F7469103E69B795C6EFBFCBC84E4756F0DDDAA6858FF32C1D74BB42694C9A2905E6504CD2F1BEFC527B2B2F0
Claims_Chart-3P.RELEVANCE.pdf	82740D02B0A6410A4446F6305F075750F9B088D290D430DEF8F513C27A4D30AD53A6BBCB9A125BCC70E76883E888B2D2D846E3921548E2DA054C55C0701D7AA3
Claims_Chart-3P.RELEVANCE.pdf	F16E3596195AAC3C138A87CF23D5850DE99929B885DD7705B287FDB8BD654A08562D13E6EC45F6114DDBA07FB3801815714FDF64861B572968E5C8462418C137
Claims_Chart-	62C028150AEDBDC74E452172D76D2534D51A4412E9328E948

3P.RELEVANCE.pdf	D346CBB9CCEA50DFB29D8EAFA7DB3DB2806415C374F21A0244251B41C5243173023CB5C40ABAE73
Claims_Chart-3P.RELEVANCE.pdf	6F5D9409CF62C1BDA5C31DBD2520858595928462460 8AD0D8FC3DC61F72B5262F097132A7D78E4E812B0DB1225B18D033690ED64661DDBB452375CE2E054B38B
Claims_Chart-3P.RELEVANCE.pdf	704B442D5F257F63547FF649D3F2B5E4AC44F3036FDABD3EA13DF63B49AE4588779CAC4C1AAF4EAC9BB165BB56E927846AD56EA9FA63DF2C7FA4A7B4CC3EE92F
1_WO2019081764A1.pdf	D97C5AA1B764853B03E06552302F75F0D3A19CC3E4C9FF621613C6135D0A9AF701F1CC57B07F3A47DBD4C80B75C00F8A375CF5FDCE78D6C7D1A83D04D5048CA9
1_WO2019081764A1-FOR.pdf	9D0EF8A10CFA9404ED985A1D9F0CE018DCCF7301A78085AA50F53B0FD63EC323921CB321EED4736F8ADF11CB1813013D6C8DE4755E241EC2F0AFD4C0FAF9F3AE
2_SOUZA.pdf	47EBA56731768F2EDB140DBAFA42E7054DCA043E3DE49FE999D52C486799F4FB3FB5C3613898A206A56EAABF801C63A0965D9535ACD58C741D343FC4FDE192F7
2_SOUZA-NPL.pdf	FA3419EA548DCF2D10D7E97D4FB2245F2C17EDBCB076D735BE79BD1034DF3D97CB729C81086BC3D494A8C45D7B4FC17EC9B4691177CAB98860522B5525D37774
3_INNEREXPLORER.pdf	CAB7E8EA85766BC0A7EDD744AB179749A96B88A49ECEFCF6F33C2748EBCD1DE1615FD095DA0C63646C6A04480760EA2F847A0A6202A707519F55CD26D24F68CF
3_INNEREXPLORER-NPL.pdf	6134E6E8C41A751639A0ED9E3EC60844EDC2C7349FDB5CA4538AF5D77168AEF8E1B61E7EF2CBE0ABB36375F081EE019C6E944B920D32A39569AE301AFCDB3E13
4_1108.pdf	AB24F959DBAFDD94A0DC791B947CE94EBBF8AA2F8C6D9B1510CA5B22270D8A2A9F1AF1B2CE6FE8F40CA66005A4B513460DB8C1D6571911B8189DD6250DF32D28
4_1108-NPL.pdf	111126675FC0DD376AD95AD296D4EA2D2128022E34B6946C7

	7F682FF6834622E0C82CA3636C9F5A945F1B6039D72B7D1F8B0A547B3DF9CC8EAEBFFF58CE07582
5_OSORIO.pdf	650D5BB88C960016505C7215D3B81788734E2EDA30BD7A911307B31A2D9FB55546ABCA867B96C74466A9C98ADDFA21273729B49276DDAAED6A33960AF2DAF87E
5_OSORIO-NPL.pdf	200A2B63F5F2D46CFD0DFC58C1D57D11E0E29B158AA40104E43608EE9F59ABB8D7535898188F30528C60CEDB14C4D82664A6F9116AA5F6AF2B1D80336C1BF0CA
6_NUNES.pdf	A3040F98C5A459116336A20828474E5159C0B0F632BAC6FB04154C0FA640FEB0D84B5B360D6168FA884EFAAD4141A4D6406CD6C2D89FFC92ED6B928D5805EEC9
6_NUNES-NPL.pdf	471E9DA653FE1EF37C17715EAC3FB3BF589E97F62A0FB8964B9EA43E40E9D528AB842130E267AB1D283D7756603F1FDA7484F60BBF23F139A69AF86BA5AE0060
7_INSERRA.pdf	FDF8F0B5689615E40358DE6AE515C9287FAF48D6A9A0C9EA9523286ECC5F96A9F8AF93F1F425974E08546B9F284FA9C16AC7C5167AB3BF254890B1AFA8D66E45
7_INSERRA-NPL.pdf	FF4A11C295F87AA68A614EF0D4A3199737C8BA6B968788B8C0C6D7EAE0925C86C8B3FBF938A60896CFC1E686611928A10D0FC126E31370522F766EE338C97A9A
8_RENELLI.pdf	6CAD1B3BDEA18CD66C70339E3DDDEB96B8276946FF9CF8217585AC64557A388926780D13404F29A7F829ACAB1252EE7D818ABCE1281A74BDDFB1E41E9D24B62B
8_RENELLI-NPL.pdf	F10A5DF7E3C1F78F8DECFFF0AD01934A904BAF0EB3C942DA58DC1499721BC22011F6B8677E811A0623191050A37E13EE1F760B3CD2922A74FFA14980E1518AE6
9_CAMERON.pdf	3BBC52917697D6192CDFAE961AFC86EC5A4323199FCDF9721E031658555B6717FC17243473760DAAA5CA93BDEAF6260FD3171759A66EE9610511657F3C8CFDF6
9_CAMERON-NPL.pdf	A631D353F89FD4B7FC231C3E3D369CCCC27CD27B8AAFC7F

	A29DD74578D2EE67D6CDFE53BE6524D22627DDD89F633DB7907D0EC1CB1DEA94322B480B2F59FBBDE
10_DMTNEXUS.pdf	B3E5F48EC5E29C6FCBEEBDD0120F95D0CA7044D40154B8D67E3AE4078EC459728CD2DF8184B81AA54BB0FA42DC7309F4A17BA91C19CE3680882295B38AE27263
10_DMTNEXUS-NPL.pdf	5C2D3A9F7F6F864118F5658F32E2510332F7553AB1361FC0E577D37663F37717ED27C8437B90ACD7D2A7299B1D3D12D39F73777C49AF85F44546497E2E16F6F8

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
18/012,122	**11/20/2023 03:23:44 PM Z ET**	

Title of Invention

Application Information

APPLICATION TYPE		PATENT #	
CONFIRMATION #		FILED BY	Sisi Li
PATENT CENTER #	63323001	AUTHORIZED BY	-
CUSTOMER #	–	FILING DATE	12/21/2022
INTL. APPLICATION #	-	INTL. FILING DATE	-
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
CARD / 0642	**E2023AJF25238803**	**Sisi Li**

FEE CODE	DESCRIPTION	ITEM PRICE($)	QUANTITY	ITEM TOTAL($)
1818	DOCUMENT FEE FOR THIRD-PARTY SUBMISSIONS (SEE 37 CFR 1.290(F))	180.00	1	180.00
			TOTAL AMOUNT:	**$180.00**

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
18/012,122	**11/20/2023 04:03:44 PM Z ET**	

Title of Invention

Application Information

APPLICATION TYPE		PATENT #	
CONFIRMATION #		FILED BY	Sisi Li
PATENT CENTER #	63324009	FILING DATE	12/21/2022
CUSTOMER #	–	FIRST NAMED INVENTOR	
INTL. APPLICATION #	-	INTL. FILING DATE	-
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	-

Documents

TOTAL DOCUMENTS: 15

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
Third-party-notification-request.pdf	1	Request for Notification of Non-compliant Third-Party Submission	14 KB
third-party-preissuance-submission.pdf	2	Third-Party Submission Under 37 CFR 1.290	64 KB
Concise-description-generated.pdf	2	Concise Description of Relevance	33 KB
11_STRASSMAN.pdf	13	-	7892 KB
11_STRASSMAN-NPL.pdf (1-13)	13	Non Patent Literature	7880 KB

Claims_Chart.pdf		32	-	1034 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
Claims_Chart-3P.RELEVANCE.pdf	(1-32)	32	Concise Description of Relevance	946 KB
12_EROWID.pdf		1	-	226 KB
12_EROWID-NPL.pdf	(1-1)	1	Non Patent Literature	219 KB
14_GALLIMORE.pdf		11	-	1247 KB
14_GALLIMORE-NPL.pdf	(1-11)	11	Non Patent Literature	1052 KB
15_EROWID.pdf		2	-	426 KB
15_EROWID-NPL.pdf	(1-2)	2	Non Patent Literature	418 KB
16_SHROOMERY.pdf		3	-	806 KB
16_SHROOMERY-NPL.pdf	(1-3)	3	Non Patent Literature	798 KB
13_US20200179349A1.pdf		23	-	2877 KB
13_US20200179349A1-	(1-23)	23	Foreign Reference	2873 KB

FOR.pdf

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
Third-party-notification-request.pdf	5A028C936E387252DEC1AC9FF8CE1FE73C03DFE5C3463142ECB8A758BB179A5B745CB85989F1227ABB3C0FF8C41F184CA65D15087CA240705465AB91E8C864CA
third-party-preissuance-submission.pdf	3CDDC8294D666ED98E0DCC4C47673CA0AFAA6031E791D9063620D4635CAA040D48836D9A187ABD259FD4E7B12042AADAD8FCEA94FB4812A49FE6B27210F92EF4
Concise-description-generated.pdf	AC2EC01371D5D4CB72C156647CBAF966F74F650906B855200711F23DE9ADC5A0DE0753D2EC3D9CCDB9A705F73915CB227C9478AD79BC9BB725A808489B428F3C
11_STRASSMAN.pdf	87C471DF02CDA44484FE76ED7543F8FF0C1E8147BE36856B32CA7954BF9C07A7B131C6E207EB2F076D6FEC6FC0680A05F034992169063860E7CB03B3864D2D89
11_STRASSMAN-NPL.pdf	585909D21DE2F46FE8D45F80328BFB96896752AB80FC4853F41790E4420E3BEEE896104C873C557EDFB21121DC269622296CD3E889BAC5944DDECDA763EA0B83
Claims_Chart.pdf	DE5FC0433383B228748D1915919CF0440A119EBE1AF83C27571A2C375A4563C4FEC708EF508D1D7BD648B96EC9292858C4B38057FE3A27AE2B574B799E97A688
Claims_Chart-3P.RELEVANCE.pdf	E769023C73089B74EA0B7E4DEC25B0B66ADCE4B422C0D7706B27D332A4B3B789D9DE1656648E49C81D34AF51CE29B479C1E4BF0EB5E0DA27C94FE7BE1F942DD2
Claims_Chart-3P.RELEVANCE.pdf	E28C177AFFBE0B6BA2174E34F28CF0ECC01B7C32F90391424BE352CD8F1ED19D9516E3712320CF030D411DD109CDDFC02F3C0ADD9BCB897AD62648B8A2A322A6

Claims_Chart-3P.RELEVANCE.pdf	4863D11CBCDB716F063BDC145241BF624D006F82F0D7B2946B4FB8A196B639E02570D687BF1AB23F9C1D26CA273F3E8FD10112829B1A53DD933C39330612CB70
Claims_Chart-3P.RELEVANCE.pdf	BBE1391EA92CFE2629834136B1153636C87ACA73187BF6AD5FF1CF0FCC1A1004546139B77A0FDED43952F34C22BAD1D9AC6935D0F1AC43C02E9105884C3CA1B0
Claims_Chart-3P.RELEVANCE.pdf	DE4242E4DDC1B6C809C8F7AAFE20D4378D15A830E94C0ED8299B8E94CF3B91D28E7D7601CF09A1C18BFDE7E357B4F444654E0EC48D04FFDA4A4C5BDF2BE71852
Claims_Chart-3P.RELEVANCE.pdf	13DE24D9196F4AF111A49D3C11BA39F73191F49C8ED866097F46A7A5679962556D8E3A17661ABC473701FE6F29FEB9AC375C4BF2BBF693A3A833FC72F43EA3AA
12_EROWID.pdf	D87AAFDFF4769CDB8C424008D3BF6F73FB0BBBCC688E4AB46BFCD267E9EFDC6A7905B14766453393A2B57D5F9F148459DA9C61E6DFF4CEB50DC124C8E762053C
12_EROWID-NPL.pdf	F124FA984598304993A3DAEBAA4576FAAF8C48E6895C1848EEE2607F52E69EDD031AFCD0997FDB3D0B24A7ACF052025DD4979B52F7F58730D323F3AE10F0CCF6
14_GALLIMORE.pdf	F16932D3B362AF7BEA8BB4A44620ADA7A1FFC5E09DE3D6C26E4034918D03417BF5DCB63B26D9B6405BED425DB61DA4E0E053ED647947F82961FEA96063D8C166
14_GALLIMORE-NPL.pdf	E9A82CD0BEEA8544213B9848A0511349EFBE3E9DD9AF2474A40ADA7F03018E6381CFBF55F4CCAD1AE41F94B8F41447C94EFC792E35C39E67FF329DDA34175FE4
15_EROWID.pdf	3059216C86527E185402119F56BB723B704D8A062B01C9D6038313FD0AE156DFA1D54987E1113B7388C194B0B89CD63388E6151AA20E02E46901FFB9C646C6D7
15_EROWID-NPL.pdf	CEBF29E9CB398898D8535EBDAED770D66D0CFD2610C3C60E4BBFBA2A96B7D162D35ADBEEDADCEE41252CDF001190E4527520E9B2B0AD8F0BBBBAE778BFCA05E7

16_SHROOMERY.pdf	9E3FFC66A056924994CBD54372BF2AE7CE3F6FF23E56F8DEF60A3695D185E5A70943A05F24C7FFF87361642D739EC48C967104151292BBECF5149D03DFB47075
16_SHROOMERY-NPL.pdf	73BDFD3FB2A44FA78D8D23F0D7F21CA00DD72364B5696251607603CECA92E5BE6E9B21905371869862FB25CA62B840384BADD360B7DF8421E8A396B4B121BACD
13_US20200179349A1.pdf	0D1EC69A0ACEB84AD3A555FD6FF482A12E90532EC9D42529FA8F9C6898BC85F0BD3C238D3A98B4E0ECF98BA2E308240648FD2534389EADE17F1B6F7D3265C34C
13_US20200179349A1-FOR.pdf	D74824B40F7C2BB9C7490B368807DC426221F62DF13287CCA8FE2DF716EB240F29BC60C3802B7C0267B5AEA3F363B02159B7C3C3065B4B80E8F10598BD60B8A5

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
18/012,122	**11/20/2023 04:03:44 PM Z ET**	

Title of Invention

Application Information

APPLICATION TYPE		PATENT #	
CONFIRMATION #		FILED BY	Sisi Li
PATENT CENTER #	63324009	AUTHORIZED BY	-
CUSTOMER #	–	FILING DATE	12/21/2022
INTL. APPLICATION #	-	INTL. FILING DATE	-
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
CARD / 0642	**E2023AJG06196812**	**Sisi Li**

FEE CODE	DESCRIPTION	ITEM PRICE($)	QUANTITY	ITEM TOTAL($)
1818	DOCUMENT FEE FOR THIRD-PARTY SUBMISSIONS (SEE 37 CFR 1.290(F))	180.00	1	180.00
			TOTAL AMOUNT:	**$180.00**

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.